Mutation Clinical Trials in Guangzhou, Guangdong
13 recruitingGuangzhou, Guangdong, China
Showing 1–13 of 13 trials
Recruiting
Phase 2
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
MutationLung Cancer Stage III
Sun Yat-sen University120 enrolled1 locationNCT06563999
Recruiting
Not Applicable
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
Leptomeningeal MetastasisNSCLC (Advanced Non-small Cell Lung Cancer)EGFR Activating Mutation+1 more
Guangzhou University of Traditional Chinese Medicine42 enrolled1 locationNCT07348965
Recruiting
Phase 3
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC136 enrolled114 locationsNCT06127407
Recruiting
Phase 1Phase 2
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Breast CancerOvarian CancerProstate Cancer+3 more
Acerand Therapeutics (Shanghai) Limited298 enrolled14 locationsNCT06380660
Recruiting
Phase 1Phase 2
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Advanced Solid TumorsKRAS G12D Mutations
Genfleet Therapeutics (Shanghai) Inc.407 enrolled20 locationsNCT06500676
Recruiting
Phase 1Phase 2
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Wayshine Biopharm, Inc.100 enrolled12 locationsNCT06631989
Recruiting
Phase 2
Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study
Non-small Cell Lung Cancer (NSCLC)Leptomeningeal MetastasesBrain Metastases+2 more
Li-kun Chen70 enrolled1 locationNCT06728865
Recruiting
Phase 2
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
Relapse/RecurrenceAML, ChildhoodRefractory AML+2 more
Children's Hospital of Soochow University50 enrolled12 locationsNCT06316960
Recruiting
Phase 2
A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL
Acute Lymphoblastic LeukemiaAdult ALLPhiladelphia-Positive ALL+2 more
Nanfang Hospital, Southern Medical University67 enrolled1 locationNCT06220487
Recruiting
Phase 2
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
Li-Fraumeni SyndromePediatric Cancerp53 Mutations
Yang Li50 enrolled1 locationNCT06088030
Recruiting
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
Non-small Cell Lung Cancer (NSCLC)EGFR-TKI Resistant MutationEGFR-TKI Sensitizing Mutation+2 more
Sun Yat-sen University1,000 enrolled1 locationNCT01994057
Recruiting
Phase 2
Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
Her-2 Negative Breast CancerHRR Gene Mutation
Ying Lin66 enrolled1 locationNCT05761470
Recruiting
Phase 1Phase 2
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
C-Met Exon 14 Mutation
Haihe Biopharma Co., Ltd.183 enrolled44 locationsNCT04270591